Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Vivianne C. G. Tjan-Heijnen*, Irene E. G. van Hellemond, Petronella G. M. Peer, Astrid C. P. Swinkels, Carolien H. Smorenburg, Maurice J. C. van der Sangen, Judith R. Kroep, Hiltje De Graaf, Aafke H. Honkoop, Frans L. G. Erdkamp, Franchette W. P. J. van den Berkmortel, Maaike de Boer, Wilfred K. de Roos, Sabine C. Linn, Alexander L. T. Imholz, Caroline M. Seynaeve, Dutch Breast Canc Res Grp B

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1502-1511
Number of pages10
JournalLancet oncology
Volume18
Issue number11
DOIs
Publication statusPublished - Nov 2017

Keywords

  • POSITIVE BREAST-CANCER
  • POSTMENOPAUSAL WOMEN
  • DISTANT RECURRENCE
  • TAMOXIFEN THERAPY
  • PAM50 RISK
  • SCORE
  • LETROZOLE
  • PALBOCICLIB
  • ANASTROZOLE
  • POPULATION

Cite this